Literature DB >> 28815082

Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessary.

Chantal M den Bakker1, Justin K Smit2,3, Anna M E Bruynzeel4, Nicole C T van Grieken5, Freek Daams1, Sarah Derks6, Miguel A Cuesta1, John T M Plukker3, Donald L van der Peet1.   

Abstract

BACKGROUND: Patients with pathologic limited or no response (pNR) to neoadjuvant chemoradiation (nCRT) are subjected to curative intended esophagectomy with subsequent perioperative morbidity and mortality, but potentially only harm from nCRT. The primary aim of this study was to compare the overall survival (OS) of patients with pNR and patients who underwent primary esophagectomy to evaluate potentially benefits of nCRT in these patients. The secondary aim was to identify predictive clinicopathologic factors for pNR and pathologic complete response (pCR) to nCRT with the goal to preselect these patients before the start of treatment.
METHODS: From the period 2005 to 2016, 206 esophageal cancer (EC) patients treated with Carboplatin/Paclitaxel and radiotherapy with complementary esophagectomy were included in this cohort. OS of patients with pNR was compared with a historical cohort of primary surgically treated patients (n=218) after a propensity score matching resulting in a group of 68 patients with pNR after nCRT versus a group of 68 primary esophagectomy patients.
RESULTS: The OS in the pNR group and the primary esophagectomy group was comparable (P=0.986). No predictive factors were found in this cohort for pNR. Female gender (OR 2.5, 95% CI 1.2-5.3) and squamous cell carcinoma (SCC) (OR 2.6, 95% CI 1.3-5.3) were identified as independent predictive factors for pCR.
CONCLUSIONS: Patients with a pNR do not benefit from nCRT followed by resection. These patients had a similar OS as those who had a primary esophagectomy alone. Although this indicates that nCRT does not negatively impact the OS of patients with pNR, patients still have an increased morbidity because of nCRT. Hence, it is important to identify factors that predict pNR. The ability to predict pNR (and pCR) will enable tailored and personalized care preventing unnecessary nCRT with increased morbidity.

Entities:  

Keywords:  Esophageal neoplasms; complete pathological response; neoadjuvant chemoradiation (nCRT); non-responders; predictive factors

Year:  2017        PMID: 28815082      PMCID: PMC5538978          DOI: 10.21037/jtd.2017.06.123

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  27 in total

1.  Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.

Authors:  George W Dittrick; Jill M Weber; Ravi Shridhar; Sarah Hoffe; Marcovalerio Melis; Khaldoun Almhanna; James Barthel; James McLoughlin; Richard C Karl; Kenneth L Meredith
Journal:  Ann Surg Oncol       Date:  2011-11-02       Impact factor: 5.344

2.  Adjuvant radiation therapy and lymphadenectomy in esophageal cancer: a SEER database analysis.

Authors:  Ravi Shridhar; Jill Weber; Sarah E Hoffe; Khaldoun Almhanna; Richard Karl; Kenneth Meredith
Journal:  J Gastrointest Surg       Date:  2013-06-08       Impact factor: 3.452

3.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

4.  A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followed by surgery or surgery alone.

Authors:  Kenneth A Kesler; Paul R Helft; Elizabeth A Werner; Neel P Jain; Jo Ann Brooks; John M DeWitt; Julia K Leblanc; Naomi S Fineberg; Lawrence H Einhorn; John W Brown
Journal:  Ann Thorac Surg       Date:  2005-04       Impact factor: 4.330

5.  Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy.

Authors:  Pooja R Rohatgi; Stephen G Swisher; Arlene M Correa; Tsung T Wu; Zhongxing Liao; Ritsuko Komaki; Garrett L Walsh; Ara A Vaporciyan; David C Rice; Robert S Bresalier; Jack A Roth; Jaffer A Ajani
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

6.  Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response.

Authors:  Pooja Rohatgi; Stephen G Swisher; Arlene M Correa; Tsung-T Wu; Zhongxing Liao; Ritsuko Komaki; Garrett L Walsh; Ara A Vaporciyan; David C Rice; Jack A Roth; Jaffer A Ajani
Journal:  Cancer       Date:  2005-12-01       Impact factor: 6.860

7.  American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.

Authors:  Nabil P Rizk; Ennapadam Venkatraman; Manjit S Bains; Bernard Park; Raja Flores; Laura Tang; David H Ilson; Bruce D Minsky; Valerie W Rusch
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

8.  Nomogram for predicting the benefit of neoadjuvant chemoradiotherapy for patients with esophageal cancer: a SEER-Medicare analysis.

Authors:  Robert Eil; Brian S Diggs; Samuel J Wang; James P Dolan; John G Hunter; Charles R Thomas
Journal:  Cancer       Date:  2013-11-05       Impact factor: 6.860

9.  Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.

Authors:  David P Kelsen; Katryn A Winter; Leonard L Gunderson; Joanne Mortimer; Norman C Estes; Daniel G Haller; Jaffer A Ajani; Walter Kocha; Bruce D Minsky; Jack A Roth; Christopher G Willett
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

10.  Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol.

Authors:  Bo Jan Noordman; Joel Shapiro; Manon Cw Spaander; Kausilia K Krishnadath; Hanneke Wm van Laarhoven; Mark I van Berge Henegouwen; Grard Ap Nieuwenhuijzen; Richard van Hillegersberg; Meindert N Sosef; Ewout W Steyerberg; Bas Pl Wijnhoven; J Jan B van Lanschot
Journal:  JMIR Res Protoc       Date:  2015-06-29
View more
  5 in total

1.  Patients with Non-response to Neoadjuvant Chemoradiation for Esophageal Cancer Have No Survival Advantage over Patients Undergoing Primary Esophagectomy.

Authors:  Guillaume S Chevrollier; Danica N Giugliano; Francesco Palazzo; Scott W Keith; Ernest L Rosato; Nathaniel R Evans Iii; Adam C Berger
Journal:  J Gastrointest Surg       Date:  2019-02-26       Impact factor: 3.452

2.  Morphomic Factors Associated With Complete Response to Neoadjuvant Therapy in Esophageal Carcinoma.

Authors:  Chien-Hung Chiu; Peng Zhang; Andrew C Chang; Brian A Derstine; Brian E Ross; Binu Enchakalody; Nidhi V Shah; Stewart C Wang; Yin-Kai Chao; Jules Lin
Journal:  Ann Thorac Surg       Date:  2019-09-21       Impact factor: 4.330

3.  A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation.

Authors:  Yimin Li; Marcus Beck; Tom Päßler; Chen Lili; Wu Hua; Ha Dong Mai; Holger Amthauer; Matthias Biebl; Peter C Thuss-Patience; Jasmin Berger; Carmen Stromberger; Ingeborg Tinhofer; Jochen Kruppa; Volker Budach; Frank Hofheinz; Qin Lin; Sebastian Zschaeck
Journal:  Sci Rep       Date:  2020-10-19       Impact factor: 4.379

4.  Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies.

Authors:  Leonie K de Klerk; Ruben S A Goedegebuure; Adam J Bass; Sarah Derks; Nicole C T van Grieken; Johanna W van Sandick; Annemieke Cats; Jurrien Stiekema; Rosa T van der Kaaij; Arantza Farina Sarasqueta; Manon van Engeland; Maarten A J M Jacobs; Roy L J van Wanrooij; Donald L van der Peet; Aaron R Thorner; Henk M W Verheul; Victor L J L Thijssen
Journal:  Mol Oncol       Date:  2021-02-23       Impact factor: 6.603

5.  The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer.

Authors:  G W van Pelt; J A Krol; I M Lips; F P Peters; D van Klaveren; J J Boonstra; W O de Steur; R A E M Tollenaar; A Farina Sarasqueta; W E Mesker; M Slingerland
Journal:  Clin Transl Radiat Oncol       Date:  2019-11-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.